Roflumilast (Daliresp)

is substantial. Quality of life, morbidity, and mortality are all negatively affected by the disease. In the National Health and Nutrition Examination Sur vey (NHANES), conducted from 1988 to 1994, the estimated prevalence of mild COPD in Americans 25 to 75 years of age was 6.9% and the prevalence of moderate COPD was 6.6%.5 This was equivalent to approximately 35 million individuals living with COPD in the U.S. Moreover, morbidity data suggest that emergency department visits and hospitalization are significantly more common in persons with COPD than in the general population; this trend is expected to increase as the population ages.6,7 COPD is currently the fourth major cause of death in the U.S. and is expected to become the third major cause of death by 2020.8 With these high morbidity and mor-